Evidence map›Paper›PMID 27793583›Full record

ArticleEBioMedicine2016

Assessment of Human Tribbles Homolog 3 Genetic Variation (rs2295490) Effects on Type 2 Diabetes Patients with Glucose Control and Blood Pressure Lowering Treatment.

Fazhong He, Mouze Liu, Zhangren Chen, Guojing Liu, Zhenmin Wang, Rong Liu, Jianquan Luo, Jie Tang, Xingyu Wang, Xin Liu and 4 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Frontiers in genetics · 2022
    Article
  7. Annals of translational medicine · 2020
    Article
  8. Article
  9. Article
  10. Polytropic Influence ofFrontiers in pharmacology · 2019
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Fazhong HeDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China.
Mouze LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China.
Zhangren ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China.
Guojing LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China.
Zhenmin WangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China.
Rong LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China.
Jianquan LuoHunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China.
Jie TangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China.
Xingyu WangBeijing Hypertension League Institute, 24 Shijingshan Road, Beijing 100043, China.
Xin LiuBeijing Hypertension League Institute, 24 Shijingshan Road, Beijing 100043, China.
Honghao ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China.
Xiaoping ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China.
Zhaoqian LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China.
Wei ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China. Electronic address: yjsd2003@163.com.
Central South University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effects of human tribbles homolog 3 (TRIB3) genetic variation (c.251 A>G, Gln84Arg, rs2295490) on the clinical outcomes of vascular events has not been evaluated in patients with type 2 diabetes after blood pressure lowering and glucose controlling treatment. We did an analysis of a 2×2 factorial (glucose control axis and blood pressure lowering axis) randomized controlled clinical trial at 61 centers in China, with a follow-up period of 5years. The major vascular endpoints were the composites of death from cardio-cerebral vascular diseases, non-fatal stroke and myocardial infraction, new or worsening renal and diabetic eye disease. A total of 1884 participants were included in our research with a 4.8years median follow-up. For glucose lowering axis, patients with TRIB3 (rs2295490) AA (n=609) genotype exhibited significantly reduced risk of major vascular events compared with AG+GG (n=335) genotype carriers (Hazard ratio 0.72, 95% CI 0.55-0.94, p=0.016), Paradoxically, the risk of vascular events were significantly increased in patients with AA (n=621) compared to AG+GG (n=319) genotype for intensive glucose control (Hazard ratio 1.46, 95% CI, 1.06–2.17, p = 0.018) [corrected]. . For blood pressure lowering axis, marginally significant difference was found between TRIB3 variant and coronary events. Our findings suggest that good glucose and blood pressure control exhibited greater benefits on vascular outcomes in patients with TRIB3 (rs2295490) G allele.

Indexed as

Genetic VariationAgedAllelesAntihypertensive AgentsBlood GlucoseBlood PressureCell Cycle ProteinsComorbidityDiabetes Mellitus, Type 2FemaleGenetic Association StudiesGenotypeHumansHypertensionMaleMiddle AgedAntihypertensive AgentsBlood GlucoseCell Cycle ProteinsProtein Serine-Threonine KinasesRepressor ProteinsTRIB3 protein, humanHypertensionIndividualized drug therapyPharmacogeneticsTRIB3Type 2 diabetes

Identifiers

PMID27793583
PMCPMC5264271
OpenAlexW2533116893

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.